<DOC>
	<DOCNO>NCT01478737</DOCNO>
	<brief_summary>To evaluate intravitreal Ozurdex reduce incidence recurrent vitreous hemorrhage primary par plana vitrectomy ( PPV ) patient proliferative diabetic retinopathy ( PDRP ) .</brief_summary>
	<brief_title>Intravitreal Ozurdex After Pars Plana Vitrectomy Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>To perform randomize , control , study patient undergo PPV vitreous hemorrhage secondary PDRP . Half patient receive intravitreal Ozurdex implant immediately surgery . The primary outcome measure proportion patient , due rebleeding within 12 month , second PPV . Secondary outcome measure include number episode vitreous hemorrhage occur within 12 month surgery clear spontaneously .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients vitreous hemorrhage undergo PPV PDRP Previous PPV Vitreous hemorrhage nonPDRP origin</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PDRP</keyword>
	<keyword>vitreous hemorrhage</keyword>
	<keyword>vitrectomy</keyword>
</DOC>